Key takeaway: The investor presentation for Aster DM Quality Care Limited, dated August 5, 2026, detailed the company's performance for the quarter ending June 30, 2026, following the merger that became effective on July 1, 2026. Management reported a 20% year-over-year revenue growth, reaching INR 2,597 crore, driven by a 13% increase in patient volumes. The merged entity achieved a 30% increase in operating EBITDA to INR 576 crore, with an EBITDA margin improvement of 170 basis points to 22.2%. The presentation highlighted the successful integration of operations with zero service disruption across 41+ sites and the establishment of a unified brand. Management noted the growth potential from both brownfield and greenfield expansions and emphasized the backing of Blackstone as a strategic advantage. The document also outlined the company's operational metrics, including a total patient volume of approximately 8 million and a workforce of over 37,700.

Key takeaway: The investor presentation from Aster DM Healthcare Limited, dated June 3, 2026, outlines the company's financial performance and strategic developments, including the merger with Quality Care India Limited (QCIL). The merger aims to create one of India's top three hospital chains, increasing bed capacity to 10,623 and projected revenue to INR 9,273 crore. The presentation highlights Aster's operational metrics, reporting a 20.4% operating EBITDA margin and a 61% occupancy rate as of FY26. Management noted a 14% revenue growth year-over-year, driven by improved patient volumes and operational efficiencies. The document also emphasizes the company's commitment to enhancing healthcare accessibility and quality through strategic expansions and technological investments. Additionally, it details the governance structure post-merger, with equal representation from Aster and Blackstone on the board. The presentation concludes with a focus on future growth potential and the importance of maintaining high operational standards.

Key takeaway: On May 1, 2026, Aster DM Healthcare held its earnings conference call for Q4 and FY26, where management discussed the company's performance and the ongoing merger with Quality Care. Management reported an 18% year-on-year revenue growth for the quarter, reaching INR 2,361 crores, driven by increased patient volumes and improved operational efficiency. The combined proforma performance indicated a strong trajectory, with Operating EBITDA growing by 25% to INR 517 crores. For FY26, the combined revenue was INR 9,273 crores, a 14% increase, with Operating EBITDA rising 21% to INR 2,013 crores. Management highlighted disciplined capacity expansion, adding 373 beds, and plans for further growth. The merger received significant shareholder approval, and regulatory processes are underway. Management emphasized a focus on clinical excellence and operational efficiency to enhance long-term value for stakeholders.

Key takeaway: The investor presentation for Aster DM Healthcare Limited detailed the company's performance for the quarter and year ended March 31, 2026. The combined entity, including Quality Care, reported an 18% year-over-year revenue growth, reaching INR 2,361 crores in Q4FY26, with total patient volumes increasing by 12% to 1.93 million. The EBITDA grew by 25% year-over-year to INR 517 crores, with margins improving to 21.9%. The merger proposal received 96.68% shareholder approval and is set to complete in Q1 FY27. Aster added 373 beds over the year, bringing total capacity to 10,623 beds. The presentation highlighted strong growth across various regions, with notable increases in revenue from Kerala and Andhra Pradesh. Management emphasized operational efficiencies and cost management as key drivers of performance, alongside a focus on expanding bed capacity and enhancing service offerings.

Key takeaway: The earnings conference call for Aster DM Healthcare Limited on February 2, 2026, discussed the company's performance for the quarter and nine months ended December 31, 2025. Management highlighted a 15% year-on-year revenue growth on a combined proforma basis with Quality Care, reaching INR 2,366 crore, driven by increased patient volumes and improved operational efficiency. Operating EBITDA grew 22% to INR 503 crore, with a stable margin of 21%. The merger with Quality Care is progressing, with key regulatory approvals received, and a shareholders' meeting scheduled for late February to approve the merger scheme. Aster's individual revenue increased by 13% to INR 1,186 crore, supported by a strong performance in oncology and medical value travel. The company plans to expand capacity significantly, adding over 4,000 beds in the coming years. Management emphasized ongoing investments in clinical talent and operational efficiencies to sustain growth.

Key takeaway: The investor presentation from Aster DM Healthcare Limited detailed the company's performance and strategic developments as of February 2026. It highlighted the merger with Quality Care India Limited, which aims to create one of the top three hospital chains in India with over 10,625 beds. The presentation reported a 15% year-over-year revenue growth for the combined entity, reaching INR 2,366 crores in Q3FY26, alongside a 22% increase in EBITDA. Aster DM's operational metrics included a 20.3% operating EBITDA margin and a 61% occupancy rate across its 202 hospitals. The document emphasized the company's commitment to enhancing patient care through a diversified healthcare ecosystem, including hospitals, pharmacies, and labs. Additionally, it outlined ongoing expansions and capital investments to strengthen its market position. The presentation concluded with a focus on maintaining high standards of clinical excellence and operational efficiency.